Loading…
Filana Therapeutics, Inc. is projected to rise to $1.90 by 2027, a +27% move from its current price of $1.50. FLNA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean neutral.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.45 | $1.50 | $1.55 | +0.02% |
| May 30 | $1.43 | $1.50 | $1.58 | +0.03% |
| May 31 | $1.41 | $1.50 | $1.60 | +0.05% |
| Jun 1 | $1.40 | $1.50 | $1.61 | +0.06% |
| Jun 2 | $1.39 | $1.50 | $1.63 | +0.08% |
| Jun 3 | $1.38 | $1.50 | $1.64 | +0.09% |
| Jun 4 | $1.37 | $1.50 | $1.65 | +0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.37 | $1.50 | $1.65 | +0.11% |
| Week 2 | $1.32 | $1.50 | $1.72 | +0.22% |
| Week 3 | $1.28 | $1.50 | $1.77 | +0.33% |
| Week 4 | $1.25 | $1.51 | $1.82 | +0.44% |
| Week 5 | $1.22 | $1.51 | $1.86 | +0.56% |
| Week 6 | $1.20 | $1.51 | $1.90 | +0.67% |
| Week 7 | $1.18 | $1.51 | $1.94 | +0.78% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Filana Therapeutics, Inc. is a clinical stage biotechnology company that develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood.
The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
Filana is positioned in the Healthcare sector. The description places Filana in the healthcare field as a biotechnology company focused on neurodegenerative diseases and related diagnostics.
Filana Therapeutics, Inc. (FLNA) is a biotechnology company operating in the Healthcare sector. It currently trades at $1.50 per share and has a market capitalization of $72.46M. Its market ranking stands at 4372 in the equity universe.
The near‑term price outlook is shaped by a multi‑year forecast that projects gradual appreciation in average price. The 2026 forecast lists an average price of $1.50, rising through 2027 to $1.90 and 2028 to $2.04, then moving higher in the subsequent years through 2050.
Across years, the forecast shows bullish sentiment beginning in 2027 and persisting thereafter. Expected returns rise from an ROI of 0% in 2026 to a peak of 306.9% by 2050, with notable mid‑course milestones such as 2030 at 35.3%, 2040 at 184.8%, and 2050 at 306.9%.
A major floor 40.0% below — a decisive break under it would weaken the trend.
The nearest floor, 21.3% below — buyers have tended to step in here.
The nearest ceiling, 17.3% above — a clean break opens room to run.
A major ceiling 63.3% above — clearing it would confirm fresh momentum.
Key FLNA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of FLNA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.35 | Buy | $1.38 | Buy |
| MA 10 | $1.28 | Buy | $1.34 | Buy |
| MA 20 | $1.33 | Buy | $1.37 | Buy |
| MA 50 | $1.56 | Sell | $1.56 | Sell |
| MA 100 | $1.84 | Sell | $1.84 | Sell |
| MA 200 | $2.37 | Sell | $2.60 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.89 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 122.25 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 15.38 | Buy |
| Bollinger %B (20,2) | 0.91 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -1.04 | Sell |
| Awesome (5,34) | -0.11 | Sell |
| Ultimate (7,14,28) | 78.42 | Sell |
| Momentum (10) | 0.30 | Buy |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 1.43 | Buy |
| ADX (14) | 27.19 | Buy |
| ATR (14) | 0.05 | Info |
The near‑term technical picture is Neutral. RSI(14) is 60, with a 50‑day moving average of $1.56 and a 200‑day moving average of $2.37. The current setup shows support at $1.18 and resistance at $1.76.
The 30‑day range spans from $1.19 to $1.90, providing a near‑term trading band. Annualized volatility sits at 70%, indicating elevated price movement relative to broader markets.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.18 | $1.50 | $2.04 | 0% | Neutral | |
| $1.46 | $1.90 | $2.64 | +27% | Bullish | |
| $1.51 | $2.04 | $2.96 | +36% | Bullish | |
| $1.52 | $2.11 | $3.18 | +41% | Bullish | |
| $1.42 | $2.03 | $3.14 | +35% | Bullish | |
| $1.40 | $2.05 | $3.26 | +37% | Bullish | |
| $1.44 | $2.17 | $3.52 | +45% | Bullish | |
| $1.61 | $2.48 | $4.11 | +65% | Bullish | |
| $1.94 | $3.05 | $5.15 | +103% | Bullish | |
| $1.89 | $3.02 | $5.20 | +101% | Bullish | |
| $2.42 | $4.27 | $7.91 | +185% | Bullish | |
| $2.91 | $6.10 | $12.56 | +307% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.18 | $1.50 | $1.76 | +0.00% |
| June 2026 | $1.24 | $1.47 | $1.78 | -2.15% |
| July 2026 | $1.27 | $1.52 | $1.88 | +3.69% |
| August 2026 | $1.26 | $1.52 | $1.90 | -0.28% |
| September 2026 | $1.21 | $1.47 | $1.86 | -3.33% |
| October 2026 | $1.24 | $1.51 | $1.93 | +3.06% |
| November 2026 | $1.29 | $1.59 | $2.05 | +5.05% |
| December 2026 | $1.27 | $1.57 | $2.04 | -1.35% |
Click any year to see its month-by-month FLNA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Filana Therapeutics, Inc.'s 2026 outlook centres on $1.50, within a $1.18 to $2.04 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, FLNA could reach as high as $2.64, with a base case around $1.90 and support toward $1.46 — roughly +27% from $1.50. Buyers look set to stay in control over this stretch.
Expect FLNA to range from $1.51 to $2.96 through 2028. The $2.04 average target implies a +36% move from current prices. That is up +7% on the projected 2027 average. Momentum favours further upside here.
The FLNA price prediction for 2029 points to an average of $2.11 (low $1.52, high $3.18) — a potential gain of +41% on today's $1.50. Buyers look set to stay in control over this stretch.
In 2030, FLNA is projected to trade between $1.42 and $3.14, averaging $2.03 — a potential gain of +35% from today's $1.50. That is -4% versus the projected 2029 average. Momentum favours further upside here.
Filana Therapeutics, Inc.'s 2031 outlook centres on $2.05, within a $1.40 to $3.26 range. That is up +1% on the projected 2030 average. That marks a +37% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, FLNA could reach as high as $3.52, with a base case around $2.17 and support toward $1.44 — roughly +45% from $1.50. Momentum favours further upside here.
Expect FLNA to range from $1.61 to $4.11 through 2033. The $2.48 average target implies a +65% move from current prices. That is up +14% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The FLNA price prediction for 2034 points to an average of $3.05 (low $1.94, high $5.15) — a potential gain of +103% on today's $1.50. Momentum favours further upside here.
In 2035, FLNA is projected to trade between $1.89 and $5.20, averaging $3.02 — a potential gain of +101% from today's $1.50. That is -1% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
Filana Therapeutics, Inc.'s 2040 outlook centres on $4.27, within a $2.42 to $7.91 range. That is up +41% on the projected 2035 average. That marks a +185% change versus current levels. Momentum favours further upside here.
By 2050, FLNA could reach as high as $12.56, with a base case around $6.10 and support toward $2.91 — roughly +307% from $1.50. Buyers look set to stay in control over this stretch.
Investing $1,000 in FLNA today (≈ 666.666667 FLNA) could be worth
$4,068.46
+$3,068.46 (+307%) by 2050 · US Dollar
Based on the average projected FLNA price of $6.1 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in FLNAwould be worth at today's price.
$1,000 invested in FLNA on May 27, 2025 (≈ 469.483543 FLNA) would be worth
$704.23
-$295.77 (-29.6%) today · 0.70× · US Dollar
Based on a FLNA entry price of $2.13 vs. today's $1.5.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.25 | $1,200 | +20.0% |
| 1 month ago | $1.56 | $961.54 | -3.8% |
| 3 months ago | $2.35 | $638.3 | -36.2% |
| 6 months ago | $3.25 | $461.54 | -53.8% |
| 1 year ago | $2.13 | $704.23 | -29.6% |
| All time (5.0y) ago | $57.06 | $26.29 | -97.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our FLNA forecast.
Our base-case forecast reaches $3.00 around 2034.
Implied market cap at $3.00: $144.92M
The multi‑year forecast shows a bullish trajectory for Filana’s price, with the average price rising from $1.50 in 2026 to $6.10 by 2050. The ROI escalates along the path, with 2030 at 35.3%, 2040 at 184.8%, and 2050 at 306.9%.
Sentiment remains bullish from 2027 onward, with notable annual averages such as 2033 at $2.48 and 2034 at $3.05, continuing to climb into the 2040s and 2050s. Key drivers cited by the forecast include ongoing work on simufilam in Phase 3 for Alzheimer’s disease and the SavaDx program as an early‑stage diagnostic program. However, outcomes in clinical development and regulatory decisions could alter this path.
These figures are estimates, not guarantees, and reflect varying levels of uncertainty inherent to clinical‑stage biotechnology. Investors should consider the potential for high volatility and the dependence on trial results and regulatory review when interpreting the outlook.
Tap a question to reveal the answer.
In 2030 the forecast shows an average price of $2.03, a min of $1.42, and a max of $3.14 with an ROI of 35.3% and bullish sentiment. The data also indicates a 2030 average price path consistent with a bullish longer‑term trend toward the 2030s.
Forecasts indicate a bullish longer‑term trajectory, with an average price rising from $1.50 in 2026 to $6.10 by 2050 and a cumulative ROI reaching 306.9% in 2050. Notable years include 2027 (avg $1.90, ROI 26.7%), 2030 (avg $2.03, ROI 35.3%), and 2040 (avg $4.27, ROI 184.8%). These are estimates and not guarantees.
The forecast shows several years with max prices near or above $5. In 2034 the max is $5.15 and in 2035 the max is $5.20, with 2033 and earlier years below $5 on average. The 2040 max is $7.91 and the 2050 max is $12.56, indicating potential for higher levels if the trajectory continues.
The current price is $1.50 and the market capitalization is $72.46M. The stock is ranked 4372 by market position.
The 30‑day technical picture is Neutral with RSI(14) at 60, a 50‑day SMA of $1.56, and a 200‑day SMA of $2.37. Support is at $1.18 and resistance at $1.76. The 30‑day range is $1.19 to $1.90 and annualized volatility is 70%.
Filana Therapeutics, Inc. Community Discussion
0Share your Filana Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.